You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed or refractory B-Cell Leukemia

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • QH103 Cell Injection
  • +2 more
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Sep 21, 2023

B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • HY004
  • +2 more
  • (no location specified)
Aug 18, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • (no location specified)
Oct 10, 2023

Refractory B-cell Acute Lymphoblastic Leukemia Trial in Houston (Mosunetuzumab)

Not yet recruiting
  • Refractory B-cell Acute Lymphoblastic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2023

Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia Trial in Tianjin (CC312)

Recruiting
  • Non-hodgkin Lymphoma
  • +2 more
  • CC312
  • Tianjin, Tianjin, China
    InstituteHBDH
Sep 12, 2023

PET-CT Imaging in Relapsed/Refractory Acute Leukemias

Not yet recruiting
  • B Cell
  • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 4, 2023

    B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Trial (Blinatumomab)

    Not yet recruiting
    • B Precursor Acute Lymphoblastic Leukemia
    • Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
    • (no location specified)
    Sep 25, 2023

    Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus

    Not yet recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +5 more
    • CD19 specific Chimeric Antigen Receptor T Cell
    • Columbus, Ohio
      Nationwide Children's Hospital
    Mar 9, 2023

    B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Unspecified Trial in Guangzhou, Guanzhou (CD19 CAR T-Cell(CAT19T2))

    Not yet recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • B-Cell Lymphoma, Unspecified
    • CD19 CAR T-Cell(CAT19T2)
    • Guangzhou, Guangdong, China
    • +1 more
    Nov 4, 2022

    Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

    Recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • +6 more
    • Beijing, China
      Beijing Cancer Hospital
    Feb 6, 2023

    CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL Trial in Suzhou (Treatment)

    Recruiting
    • CAR
    • +2 more
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Dec 27, 2022

    Relapsed/Refractory Chronic Lymphocytic Leukemia Trial in Tianjin (GNC-035)

    Not yet recruiting
    • Relapsed/Refractory Chronic Lymphocytic Leukemia
    • Tianjin, Tianjin, China
      Institute of Hematology and Blood Diseases Hospital, Chinese Aca
    Jul 13, 2023

    ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory Trial (Tafasitamab)

    Not yet recruiting
    • ALL, Childhood B-Cell
    • +2 more
    • Tafasitamab
    • (no location specified)
    Nov 25, 2022

    B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)

    Recruiting
    • B-Cell Non Hodgkin Lymphoma
    • B-Cell Acute Lymphoblastic Leukemia
    • anti-CD19 CAR T-cells
    • Hanoi, Vietnam
      Vinmec Research Institute of Stem Cell and Gene Technology
    Sep 5, 2023

    Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children, Lymphoblastic Leukemia, Acute Adult Trial in Singapore (Anti-CD19

    Recruiting
    • Lymphoblastic Leukemia
    • +5 more
    • Anti-CD19 CAR T-cells
    • Singapore, Singapore
    • +1 more
    Dec 4, 2022

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo

    Not yet recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +5 more
    • São Paulo, Brazil
      Hospital Israelita Albert Einstein
    Jan 20, 2023

    Relapsed/Refractory Acute Myeloid Leukemia Trial in Hefei (gdT cell injection targeting B7-H3 chimeric antigen receptor)

    Recruiting
    • Relapsed/Refractory Acute Myeloid Leukemia
    • gdT cell injection targeting B7-H3 chimeric antigen receptor
    • Hefei, Anhui, China
      PersonGen Anke Cellular Therapeutice Co., Ltd.
    Jan 31, 2023

    B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine

    Not yet recruiting
    • B-cell Non Hodgkin Lymphoma
    • Chronic Lymphocytic Leukemia
    • Cyclophosphamide injection
    • +2 more
    • Charleston, South Carolina
      Hollings Cancer Center at Medical University of South Carolina
    Jan 18, 2023

    Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt

    Not yet recruiting
    • Relapsed/Refractory Waldenstrom Macroglobulinemia
    • +3 more
    • Brexucabtagene Autoleucel
    • +2 more
    • (no location specified)
    Sep 8, 2022

    Relapsed/Refractory Acute Myeloid Leukemia Trial in Hangzhou (B7-H3 target, CAR gene modified gdT cell injection)

    Recruiting
    • Relapsed/Refractory Acute Myeloid Leukemia
    • B7-H3 target, CAR gene modified gdT cell injection
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital， Zhejiang University School of Med
    Feb 15, 2023

    Acute Lymphocytic Leukemia Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

    Recruiting
    • Acute Lymphocytic Leukemia
    • CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
    • Tianjin, Tianjin, China
      Hematology Hospital, Chinese Academy of Medical Sciences
    Feb 5, 2023

    Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent, Mantle Cell Lymphoma Refractory Trial in Orange,

    Recruiting
    • Follicular B-cell Non-Hodgkin's Lymphoma
    • +7 more
    • MB-106
    • Orange, California
    • +3 more
    Nov 1, 2022

    Patients Who Received Inotuzumab Ozogamicin for B-cell ALL That

    Not yet recruiting
    • Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
    • Inotuzumab Ozogamicin
    • (no location specified)
    Nov 3, 2022